Complete Genome Sequence of the Itraconazole Decreased Susceptible Madurella fahalii Type-Strain CBS 129176

Mickey Konings; Bert Gerrits van den Ende; Mirthe W J Raats; Ahmed Hassan Fahal; Wendy W J van de Sande; Ferry Hagen

doi:10.1007/s11046-023-00807-0

Complete Genome Sequence of the Itraconazole Decreased Susceptible Madurella fahalii Type-Strain CBS 129176

Mycopathologia. 2024 Jan 17;189(1):6. doi: 10.1007/s11046-023-00807-0.

Authors

Mickey Konings¹, Bert Gerrits van den Ende², Mirthe W J Raats², Ahmed Hassan Fahal³, Wendy W J van de Sande⁴, Ferry Hagen^{2

5

6}

Affiliations

¹ Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
² Department of Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.
³ The Mycetoma Research Center, University of Khartoum, Khartoum, Sudan.
⁴ Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. w.vandesande@erasmusmc.nl.
⁵ Institute for Biodiversity and Ecosystems Dynamics, University of Amsterdam, Amsterdam, The Netherlands.
⁶ Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Abstract

Madurella fahalii is a causative agent of the implantation mycosis mycetoma with decreased susceptibility to itraconazole, the preferred therapeutic drug to combat mycetoma. Here, we report the M. fahalii type-strain CBS 129176 genome assembly and annotation to identify a glutamic acid insert near the azole-binding pocket in the Cyp51A protein.

Keywords: De novo genome assembly; Decreased itraconazole susceptibility; Madurella fahalii; Madurella mycetomatis; Nanopore sequencing.

MeSH terms

Azoles
Itraconazole / pharmacology
Madurella*
Mycetoma*

Substances

Itraconazole
Azoles

Supplementary concepts

Madurella fahalii